In vitro hepatic metabolism of a CYP3A-mediated drug, quinine, in Adelie penguins

被引:10
|
作者
Wanwimolruk, S
Zhang, H
Coville, PF
Saville, DJ
Davis, LS
机构
[1] Univ Otago, Sch Pharm, Dunedin, New Zealand
[2] Univ Otago, Dept Zool, Dunedin, New Zealand
关键词
Antarctica; CYP3A; cytochrome P450; drug metabolism; environment; monooxygenase; penguin; quinine;
D O I
10.1016/S0742-8413(99)00079-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Very little is known about Antarctic animals' ability to metabolise or detoxify xenobiotics. The activity of cytochromes P450 subfamily 3A (CYP3A) in Adelie penguin liver was studied by incubating penguin liver microsomes with a human CYP3A substrate, quinine, and results were compared with those from human liver microsomes. The mean maximum rate of metabolism (Vmax) for quinine in penguin livers was approximately five times less (160 +/- 72 versus 574 +/- 416 pmol/mg/min; P < 0.01), and the mean Km (substrate affinity) for the formation of quinine's major metabolite (3-hydroxyquinine) was significantly greater than that observed in human livers (160 +/- 73 Versus 83 +/- 19 mu M; P < 0.01). The mean intrinsic clearance (Vmax/Km) was 1.1 +/- 0.4 mu l/min (penguin), i.e. sevenfold less than in human livers (7.4 +/- 5.9 mu l/min, P < 0.005), suggesting that penguins have much less ability than humans to eliminate xenobiotics having a similar metabolic nature to quinine (i.e. CYP3A substrates). 3-Hydroxyquinine formation in penguin liver was inhibited by specific CYP3A inhibitors, midazolam and troleandomycin, but not by other CYP inhibitors, indicating that quinine metabolism to 3-hydroxyquinine in Adelie penguin liver is likely to be catalysed by a CYP isoform resembling human CYP3A. Adelie penguin liver CYP isoforms could serve as biomarkers for the impact of environmental pollution. (C) 1999 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:301 / 307
页数:7
相关论文
共 50 条
  • [41] Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model
    Rioux, Nathalie
    Bellavance, Edith
    Bourg, Serge
    Garneau, Michel
    Ribadeneira, Maria D.
    Duan, Jianmin
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2013, 34 (07) : 396 - 401
  • [42] Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-γ agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity
    Fayer, JL
    Zannikos, PN
    Stevens, JC
    Luo, YQ
    Sidhu, R
    Kirkesseli, S
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (03): : 305 - 316
  • [43] Inhibition of CYP3A-mediated oxidation in human hepatic microsomes by the dietary derived complex phenol, gallic acid
    Stupans, I
    Tan, HW
    Kirlich, A
    Tuck, K
    Hayball, P
    Murray, M
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2002, 54 (02) : 269 - 275
  • [44] Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole
    Chien, Jenny Y.
    Lucksiri, Aroonrut
    Ernest, Charles S., II
    Gorski, J. Christopher
    Wrighton, Steven A.
    Hall, Stephen D.
    [J]. DRUG METABOLISM AND DISPOSITION, 2006, 34 (07) : 1208 - 1219
  • [45] Correlation of in vitro inhibition of midazolam CYP3A4-mediated metabolism to in vivo drug interactions
    Volpe, Donna A.
    Avaritt, Brittany R.
    [J]. DRUG METABOLISM REVIEWS, 2016, 48 : 88 - 88
  • [46] CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro
    Eagling, VA
    Wiltshire, H
    Whitcombe, IWA
    Back, DJ
    [J]. XENOBIOTICA, 2002, 32 (01) : 1 - 17
  • [47] Identification of a Cranberry Juice Product that Inhibits Enteric CYP3A-Mediated First-Pass Metabolism in Humans
    Ngo, Ngoc
    Yan, Zhixia
    Graf, Tyler N.
    Carrizosa, Daniel R.
    Kashuba, Angela D. M.
    Dees, E. Claire
    Oberlies, Nicholas H.
    Paine, Mary F.
    [J]. DRUG METABOLISM AND DISPOSITION, 2009, 37 (03) : 514 - 522
  • [48] The Use of 13C-Erythromycin as an in Vivo Probe to Evaluate CYP3A-mediated Drug Interactions in Rats
    Sugiyama, Erika
    Kikuchi, Atsuko
    Inada, Makoto
    Sato, Hitoshi
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (09) : 3995 - 4005
  • [49] Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure
    Brussee, Janneke M.
    Vet, Nienke J.
    Krekels, Elke H. J.
    Valkenburg, Abraham J.
    Jacqz-Aigrain, Evelyne
    van Gerven, Joop M. A.
    Swart, Eleonora L.
    van den Anker, Johannes N.
    Tibboel, Dick
    de Hoog, Matthijs
    de Wildt, Saskia N.
    Knibbe, Catherijne A. J.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (02) : 358 - 368
  • [50] Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?
    Wanwimolruk, S
    Paine, MF
    Pusek, SN
    Watkins, PB
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (06) : 643 - 651